BCAL Diagnostics

BCAL Diagnostics EBITDA per Share

The EBITDA per Share of BCAL Diagnostics (BDX.AX) as of Oct 18, 2026 is -0.02 AUD. In the previous year, EBITDA per Share was -0.02 AUD — a change of -25.80% (higher).

EBITDA per Share

-0.02AUD

YoY

-25.80%

Last updated:

EBITDA per Share of BCAL Diagnostics is 2025 -0.02 AUD. EBITDA per Share of BCAL Diagnostics was 2024 -0.02 AUD. It decreases by -25.80% higher compared to the previous year.

The BCAL Diagnostics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.00 AUD
Jan 1, 2019
-0.00 AUD
Jan 1, 2020
-0.00 AUD
Jan 1, 2021
-0.00 AUD
Jan 1, 2022
-0.02 AUD
Jan 1, 2023
-0.02 AUD
Jan 1, 2024
-0.02 AUD
Jan 1, 2025
-0.02 AUD
The BCAL Diagnostics EBITDA per Share history
YEAREBITDA per ShareYoY
-0.02AUD-25.80%
-0.02AUD-2.04%
-0.02AUD+48.36%
-0.02AUD+245.85%
-0.00AUD+35.69%
-0.00AUD+62.93%
-0.00AUD-5.81%
-0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

EBITDA per Share of BCAL Diagnostics is -0.02 AUD in 2025.

EBITDA per Share of BCAL Diagnostics changed from -0.02 AUD to -0.02 AUD, representing a -25.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — BCAL Diagnostics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BCAL Diagnostics